Drug Trial Radar · NCT03094403
To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel
Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Jul 1, 2016
Primary completion
Mar 31, 2017
Study completion Apr 1, 2017
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study
Conditions
- Rosacea
Interventions
Azelaic Acid 15% topical gelDrug
Gel
Finacea® (azelaic acid) Gel, 15%Drug
Gel
PlaceboDrug
Gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in inflammatory lesion countsTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.